Raptiva
(efalizumab)Phase 2Monoclonal antibody
RocheEfalizumab was used to treat moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches on the skin. It works by suppressing the immune system to reduce inflammation and improve skin appearance.[1] Raptiva is currently being investigated across 17 indications[3], with its most advanced program in Phase 2.[1]
Raptiva is one of 425 small molecule programs targeting Oral Lichen Planus. It is currently in Phase 2.
17
Indications
23
Total Trials
0
Active Trials
424
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Raptiva
RochePhase 2
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Arcoxia
NovartisPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Celexa
AbbViePreclinical
Zelhou
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Cataflam
NovartisPreclinical
Rituxan
PfizerPreclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis10 trials
Show 7 more trials
Diabetic Macular Edema1 trial
9 more indications
Rheumatoid Arthritis1 trial
Graft Versus Host Disease1 trial
De Novo Renal Transplantation1 trial
Kidney Transplant1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for efalizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]